Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Cancer Diseases

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44349   clinical trials with a EudraCT protocol, of which   7376   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    8,101 result(s) found for: Cancer Diseases. Displaying page 159 of 406.
    «« First « Previous 155  156  157  158  159  160  161  162  163  Next» Last»»
    EudraCT Number: 2015-003118-26 Sponsor Protocol Number: RAMSES/FLOT7 Start Date*: 2016-04-26
    Sponsor Name:Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
    Full Title: RAMSES / FLOT7 Perioperative RAMucirumab in combination with FLOT versus FLOT alone for reSEctable eSophagogastric adenocarcinoma RAMSES - a phase II/III trial of the AIO
    Medical condition: locally advanced resectable adenocarcinoma of the esophagogastric junction or the stomach
    Disease: Version SOC Term Classification Code Term Level
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10062878 Gastrooesophageal cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2015-002934-32 Sponsor Protocol Number: D4884C00001 Start Date*: 2015-12-15
    Sponsor Name:AstraZenenca AB
    Full Title: A Phase II, Multi-Center, Open-Label Study of Tremelimumab Monotherapy in Patients with Advanced Solid Tumors
    Medical condition: Adult patients (age ≥18 years) with advanced and metastatic solid tumors including but not limited to histologically or cytologically documented UBC, PDAC, or TNBC.
    Disease: Version SOC Term Classification Code Term Level
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033599 Pancreatic adenocarcinoma metastatic LLT
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10071664 Bladder transitional cell carcinoma metastatic PT
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10075566 Triple negative breast cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) BE (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2020-003395-41 Sponsor Protocol Number: EVIDENT Start Date*: 2021-01-15
    Sponsor Name:Oslo University Hospital
    Full Title: An open-label single arm interventional phase 2 study to investigate outcome of individualized treatment based on pharmacogenomic profiling and ex vivo drug sensitivity testing of patient-derived o...
    Medical condition: Metastatic Colorectal Cancer
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10052362 Metastatic colorectal cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-003007-19 Sponsor Protocol Number: MK-7339-002 Start Date*: 2018-11-29
    Sponsor Name:Merck Sharp & Dohme LLC
    Full Title: A Phase 2 Study of Olaparib Monotherapy in Participants with Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer
    Medical condition: Homologous recombination repair mutation (HRRm) or Homologous recombination deficiency (HRD) positive cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10065252 Solid tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Trial now transitioned) IE (Trial now transitioned) FR (Trial now transitioned) ES (Ongoing) GB (GB - no longer in EU/EEA) IT (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2011-003044-53 Sponsor Protocol Number: B1271003 Start Date*: 2012-01-30
    Sponsor Name:Pfizer Inc., 235 East 42nd Street, New York, NY 10017 US
    Full Title: AN OPEN-LABEL, RANDOMISED PHASE 1B/2 STUDY OF PF-04691502 IN COMBINATION WITH LETROZOLE COMPARED WITH LETROZOLE ALONE IN PATIENTS WITH ESTROGEN RECEPTOR POSITIVE, HER-2 NEGATIVE EARLY BREAST CANCER
    Medical condition: ESTROGEN RECEPTOR POSITIVE, HER-2 NEGATIVE EARLY BREAST CANCER WITH KI-67 HIGHER THAN 10% AND ESTROGEN RECEPTOR POSITIVE, HER-2 NEGATIVE ADVANCED BREAST CANCER
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10070575 Estrogen receptor positive breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Prematurely Ended) BE (Prematurely Ended) SE (Prematurely Ended) ES (Completed) GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-003552-23 Sponsor Protocol Number: 64091742PCR2002 Start Date*: 2018-05-10
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Phase 1b-2 Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer
    Medical condition: Metastatic castration-resistant prostate cancer (mCRPC)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10076506 Castration-resistant prostate cancer LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (GB - no longer in EU/EEA) ES (Ongoing) BE (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-002158-40 Sponsor Protocol Number: A6181120 Start Date*: 2008-07-22
    Sponsor Name:Pfizer S.A.
    Full Title: A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY OF SUNITINIB PLUS PREDNISONE VERSUS PREDNISONE IN PATIENTS WITH PROGRESSIVE METASTATIC HORMONE-REFRACTORY PROSTATE CANCER AFTER FAILURE OF A D...
    Medical condition: (mHRPC) after failure of a docetaxel-based chemotherapy regimen Cáncer de próstata resistente a las hormonas metastático (CPRHm) tras el fracaso de una pauta de quimioterapia basada en el docetaxel
    Disease: Version SOC Term Classification Code Term Level
    9.1 10062904 Hormone-refractory prostate cancer LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: ES (Prematurely Ended) GB (Prematurely Ended) SE (Completed) DE (Prematurely Ended) PT (Prematurely Ended) SK (Prematurely Ended) DK (Prematurely Ended) CZ (Prematurely Ended) FR (Completed) FI (Prematurely Ended) BE (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-003314-97 Sponsor Protocol Number: CA184-043 Start Date*: 2009-08-05
    Sponsor Name:Bristol Myers Squibb International Corporation
    Full Title: A Randomized, Double-Blind, Phase 3 Trial Comparing Ipilimumab vs. Placebo Following Radiotherapy in Subjects with Castration Resistant Prostate Cancer That Have Received Prior Treatment with Do...
    Medical condition: Castration Resistant Prostate Cancer
    Disease: Version SOC Term Classification Code Term Level
    16.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060862 Prostate cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DE (Prematurely Ended) AT (Completed) NL (Completed) IT (Completed) CZ (Completed) DK (Completed) ES (Completed) IE (Completed) BE (Completed) GB (Completed) HU (Completed) FR (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2005-000387-39 Sponsor Protocol Number: BO18255 Start Date*: 2005-07-04
    Sponsor Name:Hoffmann-La Roche Ltd/Inc/AG/Roche Global Development
    Full Title: An open-label randomized multicentre phase III study of trastuzumab in combination with a fluoropyrimidine and cisplatin versus chemotherapy alone as first-line therapy in patients with HER2 positi...
    Medical condition: Advanced gastric cancer
    Disease: Version SOC Term Classification Code Term Level
    7.1 10017767 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) ES (Completed) GB (Completed) DE (Completed) DK (Completed) BE (Completed) PT (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2013-000568-28 Sponsor Protocol Number: GO28888 Start Date*: 2014-10-16
    Sponsor Name:Genentech, Inc.
    Full Title: A phase II randomized, double-blind study of neoadjuvant letrozole plus GDC-0032 versus letrozole plus placebo in postmenopausal women with ER-positive/HER2-negative, early stage breast cancer
    Medical condition: WOMEN WITH ER-POSITIVE/HER2-NEGATIVE, EARLY STAGE BREAST CANCER
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004864 10070575 Estrogen receptor positive breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: BE (Completed) DE (Completed) AT (Completed) CZ (Completed) PT (Completed) HU (Completed) IT (Completed) GB (Completed) ES (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2009-010715-32 Sponsor Protocol Number: 20080763 Start Date*: 2009-11-17
    Sponsor Name:Amgen Inc
    Full Title: A Randomized, Multicenter, Open-label, Phase 3 Study to Compare the Efficacy and Safety of Panitumumab and Cetuximab in Subjects with Previously Treated, Wild-type KRAS, Metastatic Colorectal Cancer
    Medical condition: Previously Treated, Wild-type KRAS, Metastatic Colorectal Cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10052362 Metastatic colorectal cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LV (Completed) FR (Completed) LT (Completed) CZ (Completed) SE (Completed) BE (Completed) SK (Completed) IT (Completed) NL (Completed) GB (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2008-005425-11 Sponsor Protocol Number: 3144A2-3003/B1891003 Start Date*: 2009-01-14
    Sponsor Name:Wyeth Pharmaceuticals Inc, a wholly owned subsidiary of Pfizer Inc, 500 Arcola Road, Collegeville, PA 19426 USA
    Full Title: A Phase 2 Randomized Open Label Study of Neratinib versus Lapatinib plus Capecitabine for the Treatment of ErbB-2 Positive Locally Advanced or Metastatic Breast Cancer
    Medical condition: Locally advanced or metastatic breast cancer
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: HU (Completed) SI (Completed) BE (Completed) DE (Completed) ES (Completed) CZ (Completed) IT (Prematurely Ended) GR (Completed) FR (Completed) AT (Completed) GB (Completed) BG (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2021-001811-94 Sponsor Protocol Number: M18-868 Start Date*: 2022-01-28
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: A Phase 3 Open-Label, Randomized, Controlled, Global Study of Telisotuzumab Vedotin (ABBV-399) Versus Docetaxel in Subjects with Previously Treated c-Met Overexpressing, EGFR Wildtype, Locally Adva...
    Medical condition: C-Met overexpressing EGFR wildtype, non-squamous non-small cell lung cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10079440 Non-squamous non-small cell lung cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Trial now transitioned) CZ (Trial now transitioned) SE (Trial now transitioned) BE (Trial now transitioned) HU (Completed) FR (Trial now transitioned) RO (Trial now transitioned) AT (Trial now transitioned) IT (Trial now transitioned) NL (Trial now transitioned) ES (Ongoing) PT (Trial now transitioned) DK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-005765-23 Sponsor Protocol Number: ESR-14-10083 Start Date*: 2017-10-10
    Sponsor Name:VU Medical Centre
    Full Title: Companion biomarker development for MEDI4736 treated non-small-cell lung cancer patients using 89Zirconium-labeled MEDI4736 – a feasibility study
    Medical condition: Stadium IV non-small-cell lung cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-002045-38 Sponsor Protocol Number: SGMCLM Start Date*: 2020-03-23
    Sponsor Name:Leiden University Medical Center
    Full Title: AN OPEN-LABEL, EXPLORATORY STUDY ASSESSING THE FEASIBILITY OF SGM-101, A FLUOROCHROME-LABELED ANTI-CARCINOEMBRYONIC ANTIGEN MONOCLONAL ANTIBODY FOR THE INTRAOPERATIVE DETECTION OF LUNG METASTASIS I...
    Medical condition: Colorectal lung metastases
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052358 Colorectal cancer metastatic PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10050017 Lung cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-004901-25 Sponsor Protocol Number: MEK115892 Start Date*: 2012-07-25
    Sponsor Name:GlaxoSmithKline Research and Development Ltd
    Full Title: An Open-Label, Two-Period, Randomized, Crossover Study to Assess the Relative Bioavailability of GSK1120212 Tablet Formulation and the GSK1120212 Pediatric Oral Solution Formulation Following Si...
    Medical condition: GSK1120212 is currently being developed for a number of solid tumors, including metastatic BRAF-mutant melanoma (Phase 3), pancreatic cancer (Phase 2) and non small cell lung cancer (Phase 2), and ...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2012-000996-17 Sponsor Protocol Number: 201200099617 Start Date*: 2012-06-18
    Sponsor Name:AZIENDA UNIVERSITARIA POLICLINICO UMBERTO I DI ROMA
    Full Title: Phase II study of biweekly cabazitaxel in patients affected by castration resistant prostate cancer previously treated with docetaxel: evaluation of safety and quality of life.
    Medical condition: Subjects affected by metastatic castration refractory prostate cancer progressed or intolerant to a previous docetaxel-based chemotherapy.
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-004903-20 Sponsor Protocol Number: ABR-38376 Start Date*: 2012-05-09
    Sponsor Name:
    Full Title: Hydroxychloroquine as an anti-autophagy and chromatin modulating drug in combination with erlotinib in non-small cell lung cancer (NSCLC) patients: a single-center single arm open-label phase II trial
    Medical condition: Patients with histologically confirmed stage IV non-squamous non-small-cell lung cancer (NSCLC) • with an activating EGFR mutation who progressed on erlotinib or gefitinib monotherapy. OR • who...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-000868-34 Sponsor Protocol Number: ZKES-EcNO-2015 Start Date*: 2015-05-29
    Sponsor Name:ZKES GmbH
    Full Title: Randomized, placebo controlled phase III trial of a microbiological concomitant therapy/prevention of chemotherapeutical induced diarrhea (caused by inflammation and an impaired intestinal barrier)...
    Medical condition: Gastric or colorectal cancers, where a treatment with 5-Fluoruracil and one further chemotherapeutic remedy (either irinotecan or a platinum based chemotherapeutic remedy) is planned.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-006009-85 Sponsor Protocol Number: 1 Start Date*: 2012-06-04
    Sponsor Name:VU University medical center
    Full Title: Prediction of response to kinase inhibitors based on protein phosphorylation profiles in tumor tissue from advanced renal cell cancer patients
    Medical condition: Advanced solid tumors
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 155  156  157  158  159  160  161  162  163  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Jul 16 10:19:25 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA